Ionis Pharmaceuticals, Inc., the leader in antisense therapeutics, and its partner, AstraZeneca, announced positive data from the ETESIAN Phase 2b study of ION449, an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9.
April 4, 2022
· 7 min read